DIRS.INFO The most relevant business & tech news

☆ Novo Nordisk strikes deal worth up to $1.1 billion to expand cardio business
▼ + stars: | 2024-03-25 | by ( ) www.cnbc.com time to read: +1 min

A view of the logo of Novo Nordisk at the company's office in Bagsvaerd, on the outskirts of Copenhagen, Denmark, March 8, 2024. Denmark's Novo Nordisk said on Monday it had agreed to buy Cardior Pharmaceuticals for up to 1.03 billion euros ($1.1 billion) to strengthen its cardiovascular pipeline. The deal is in line with Novo's aim to expand its focus on diabetes and weight-loss therapies to include cardiovascular disease treatments. The Danish company has rocketed to become one of the world's most valuable companies on the back of its hugely popular weight-loss treatment Wegovy. The deal includes Cardior's lead compound CDR132L, currently in intermediate Phase II clinical trials for the treatment of heart failure, Novo said.

Persons: Novo, CDR132L Organizations: Novo Nordisk, Denmark's, Nordisk, Cardior Pharmaceuticals Locations: Bagsvaerd, Copenhagen, Denmark, Danish, Novo

☆ These stocks have the most at risk as patients on Ozempic eat less, according to Morgan Stanley
▼ + stars: | 2023-11-23 | by ( Jesse Pound | In Jesse-Pound | ) www.cnbc.com time to read: +3 min

The use of weight-loss drugs such as Ozempic is poised to change consumer consumption patterns, but not every food-related company will get hit in the same way, according to Morgan Stanley. Fast food restaurants were especially vulnerable. "Shoppers with obesity spend more at large fast food brands and, on a relative basis, less at fast casual restaurants and casual diners," Morgan Stanley said. One stock that is closer to a risky pure play is McDonald's , which is second highest on the list, according to the Morgan Stanley research. Low cost retailers like Walmart and snack and beverage companies like Pepsico are also exposed, according to the Morgan Stanley research.

Persons: Morgan Stanley, Eli Lilly, Pamela Kaufman, Kaufman, Tim Hortons, Burger, Taco Bell, — CNBC's Michael Bloom Organizations: Novo Nordisk, Denmark's Novo Nordisk, Restaurant Brands, Yum Brands, Walmart, Pepsico Locations: U.S

☆ Ozempic and other weight-loss drugs will power the anti-obesity market to 16-fold gains by 2030, Goldman Sachs says
▼ + stars: | 2023-11-04 | by ( George Glover | ) www.businessinsider.com time to read: +3 min

The anti-obesity market could become a $100 billion industry by 2030, Goldman Sachs predicts. The rise of GLP-1 weight loss drugs has meant big gains for Novo Nord Nordisk and Eli Lilly. AdvertisementAdvertisementThe anti-obesity market is primed for a massive surge over the next six years, according to Goldman Sachs. Such a gain would push its total valuation from $6 billion to as much as $100 billion. Meanwhile, Barclays and Berenberg have predicted the market's value could climb to $100 billion and $85 billion respectively.

Persons: Goldman Sachs, Eli Lilly, —, they're, Chris Shibutani, Morgan Stanley Organizations: Novo Nord Nordisk, Service, Denmark's Novo Nordisk, Barclays, Berenberg

☆ AI, weight loss drugs and more: Portfolio manager names stocks to play 'new secular growth themes'
▼ + stars: | 2023-10-24 | by ( Amala Balakrishner | ) www.cnbc.com time to read: +4 min

And then you overlay on top of that the emergence of two or three brand new secular growth themes," he said. CNBC Pro takes a look at the stocks he likes in three "brand new" areas of growth: obesity drugs, reshoring and artificial intelligence. Reshoring infrastructure Ayer sees bright spots in the reshoring theme too. The portfolio manager named tech giant Amazon as a good play of the AI wave. The way Ayer sees it, more companies in the U.S. are foraying into AI right now, compared to those in other parts of the world.

Persons: Sanjay Ayer, Ayer, He's bullish, —, Christina Cheddar Berk, Carmen Reinicke, Julie Coleman Organizations: CNBC Pro, WCM Investment Management, Equity Fund, Nordisk, Novo Nordisk, U.S . Food, Drug Administration, Tetra Tech, Canadian, Canadian Pacific, U.S Locations: U.S, China, Japan, India

☆ Novo Nordisk owner invests $290 million in energy transition fund
▼ + stars: | 2023-09-14 | by ( Maggie Fick | ) www.reuters.com time to read: +2 min

FILE PHOTO-A coffee machine featuring Novo Nordisk logo is seen at the company headquarters in Copenhagen, Denmark, February 5, 2020. REUTERS/Jacob Gronholt-Pedersen/File Photo Acquire Licensing RightsCompanies Novo Nordisk A/S FollowLONDON, Sept 14 (Reuters) - The controlling shareholder in drugmaker Novo Nordisk on Thursday announced a major investment in a new energy transition fund as it expands its portfolio beyond health. Novo Holdings controls 76% of the votes in Denmark's Novo Nordisk (NOVOb.CO), which became Europe's most valuable company last week on the back of soaring profits from its weight-loss drug Wegovy and type 2 diabetes drug Ozempic. Novo Holdings' capital to invest is burgeoning on Novo Nordisk's financial performance. Novo Holdings is wholly owned by the Novo Nordisk Foundation, which lists its aims as providing "a stable basis for the commercial and research activities conducted by the companies within the Novo Group", of which Novo Nordisk is the largest, and supporting "scientific, humanitarian, and social purposes."

Persons: Jacob Gronholt, Pedersen, Morten Beck Jorgensen, " Jorgensen, Maggie Fick, Amanda Cooper, Elaine Hardcastle Organizations: Novo Nordisk, REUTERS, drugmaker Novo Nordisk, Novo Holdings, Denmark's, Denmark's Novo Nordisk, Holdings, Glentra Capital, Glentra, Reuters, Novo, Novo Nordisk Foundation, Thomson Locations: Copenhagen, Denmark, drugmaker Novo, Denmark's Novo, Glentra Capital

☆ Weight loss drugmaker Novo Nordisk vies to become Europe's most valuable company, toppling LVMH
▼ + stars: | 2023-09-01 | by ( Jenni Reid | ) www.cnbc.com time to read: +1 min

Denmark's Novo Nordisk on Friday briefly overtook French luxury goods behemoth LVMH to become Europe's most valuable company as investors bet on the potential of its weight loss drugs. Novo Nordisk's market capitalization was $421 billion including unlisted stock at 9:43 a.m. London time, according to Refinitiv data cited by Reuters, versus LVMH's $420.97 billion. LVMH regained the top spot it previously held for two-and-a-half years by 11 a.m. London time, Refinitiv data showed, but the drugmaker remains on its heels. Novo Nordisk produces drugs Ozempic and Wegovy, which have generated massive hype over the past year over their potential weight loss uses. In August, the company released clinical trial results indicating that Wegovy reduced the risk of serious heart problems and heart-related death by 20%.

Persons: LVMH Organizations: Denmark's Novo Nordisk, Reuters, Novo Nordisk Locations: London, Denmark

☆ Trick That Helps Big Pharma Companies Avoid Paying Billons in US Taxes
▼ + stars: | 2023-08-03 | by ( Brad Setser | Tess Turner | ) www.businessinsider.com time to read: +11 min

But take a look at the corporate disclosures of America's largest pharmaceutical companies, and a puzzling hole opens. Large legal loopholesThe offshore migration of these pharmaceutical companies' profits may seem egregious, but the tax gymnastics are generally legal. On paper, America's corporate-tax rate is 21%, but the country's largest and most profitable pharmaceutical companies don't pay anything close to that. What's more, the superlow rate enjoyed by American pharmaceutical companies isn't necessary for these firms to be internationally competitive. A spoonful of medicine to make the taxes go downAmerica's pharmaceutical companies have made great contributions to medicine.

Persons: Democratic Sen, Ron Wyden, AbbVie, it's, Keytruda, Gilead, Eli Lilly, they've, Brad W, Whitney, Tess Turner Organizations: Merck, National Institutes of Health . Pharmaceutical, Democratic, Pfizer, US pharma, US Treasury, Trump, Treasury, US, Denmark's, Nordisk, Novartis, National Institutes of Health, Whitney Shepardson, Council, Foreign Relations Locations: Oregon, America, Caribbean, Europe, Bermuda, Puerto Rico, Germany, Ireland, Singapore, Switzerland, Belgium, Denmark

☆ Novo Nordisk shares slip on EMA drug safety signal
▼ + stars: | 2023-06-22 | by ( ) www.reuters.com time to read: +2 min

reported that the European Medicines Agency (EMA) had raised the safety signal, which is a way to monitor potential adverse events from the use of approved drugs. "Novo Nordisk is aware of the signal and the request by EMA and will deliver a thorough assessment of all relevant data to elucidate this topic," Lars Otto Andersen-Lange, media relations director at Novo Nordisk, told Reuters. report referred to a May 8 statement from EMA, which raised a thyroid cancer safety signal for several drugs in the GLP-1 class, including semaglutide. But a "causal association" between semaglutide and thyroid cancer had not been demonstrated in large-scale clinical trials and post-marketing surveillance, he said. EMA's safety signal had also included GLP-1 drugs from competitors Eli Lilly (LLY.N), Astrazeneca (AZN.L) and Sanofi (SASY.PA).

Persons: Lars Otto Andersen, Lange, Andersen, " Andersen, Eli Lilly, Soren Lontoft Hansen, Nikolaj Skydsgaard, Maggie Fick, Alexander Smith Organizations: Novo Nordisk, European Medicines Agency, EMA, Nordisk, Reuters, Astrazeneca, Sanofi, Thomson Locations: COPENHAGEN, Novo, Denmark's Novo, Copenhagen

☆ Novo Nordisk says EMA raised safety signal on drugs, shares fall
▼ + stars: | 2023-06-22 | by ( Nikolaj Skydsgaard | ) www.reuters.com time to read: +3 min

The European Medicines Agency (EMA) raised the safety signal, which is a way to monitor potential adverse events from the use of approved drugs. "Novo Nordisk is aware of the signal and the request by EMA and will deliver a thorough assessment of all relevant data to elucidate this topic," Lars Otto Andersen-Lange, media relations director at Novo Nordisk, told Reuters. reported the EMA safety signal. report referred to a May 8 statement from EMA, which raised a thyroid cancer safety signal for several drugs in the GLP-1 class, including semaglutide. EMA's safety signal also included GLP-1 drugs from competitors Eli Lilly (LLY.N), Astrazeneca (AZN.L) and Sanofi (SASY.PA).

Persons: Eli Lilly, Ozempic, Lars Otto Andersen, Lange, Andersen, " Andersen, Soren Lontoft Hansen, semaglutide, Nikolaj Skydsgaard, Maggie Fick, Alexander Smith Organizations: Sanofi, Novo Nordisk, European Medicines Agency, EMA, Nordisk, Reuters, Astrazeneca, FDA, Thomson Locations: Astrazeneca, COPENHAGEN, Denmark's Novo, Copenhagen

☆ Explainer: After COVID and drug shortages, EU revamps drug laws
▼ + stars: | 2023-04-03 | by ( Maggie Fick | ) www.reuters.com time to read: +5 min

The Commission aims to publish a draft - the biggest overhaul of existing medical laws in two decades - on April 26. A Commission spokesperson said: "The Commission will put forward a balanced and patient-centred proposal, whilst fully supporting an innovative and competitive industry." If the EU health regulator approves a new use for the medicine, they get another year, bringing the total to 11. Fourteen member states have written to the Commission, criticising the idea as costly and harmful for consumers as it could disrupt the generic drugs market. Once the Commission publishes the draft, the European Parliament, Commission and member states will thrash out final details.

☆ Outperforming asset manager picks the stocks set to win as margins get squeezed
▼ + stars: | 2022-11-25 | by ( Zavier Ong | ) www.cnbc.com time to read: +3 min

"Consumers are going to have their purse strings pulled by utility bills, higher mortgage costs, higher petrol prices, and there's going to be margin squeeze." He said wage pressure and higher commodity prices were particularly challenging and could eat into companies' margins. Luxury Luxury stocks are another favorite for Armstrong. Moreover, the "massive" profit margins of luxury companies are also insulated from increases in input prices, he added. Within the space, Armstrong's fund owns French luxury goods companies LVMH and Hermes , given their "defendable margins" and the ability to be price setters.

Search resuls for: "Denmark's Novo"

11 mentions found